Surginex is at the forefront of innovative next-generation lipid nanoparticle (LNP) technology, which aims to enhance the efficacy of drugs and genes while minimizing side effects. Their proprietary platform allows for precise, organ- and cell-specific delivery of various therapeutics, thereby maximizing treatment accuracy, safety, and effectiveness. This technology is integral to their mission of "Safeguarding the Suffering," as it seeks to improve patients' quality of life through advanced therapeutic solutions.

The company has developed several key platforms, including the Gallstone-dissolving Platform, which utilizes AI technology to create a non-surgical treatment for gallstones and polyps. Additionally, Surginex boasts advanced engineering capabilities in LNPs, a platform designed to promote rapid recovery from surgical wounds, and the AI Odysseus Platform, which enhances drug targeting. Their commitment to innovation is further demonstrated through their various pipelines, including the SURGI liver Platform, which aids in liver regeneration post-surgery, showcasing their comprehensive approach to addressing multiple medical conditions through cutting-edge technology.

South Korea

Surginex is a company that operates a drug discovery platform intended to develop next-generation bio platforms and new drugs. The company specializes in 361 HCT/P allografts and is committed to turning innovative scientific research into practical medical solutions.

Surginex

Company Details